Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone

Bayer

Status

Completed

Conditions

Hypogonadism

Treatments

Drug: Testosterone Product

Study type

Observational

Funder types

Industry

Identifiers

NCT03484260

19547

Details and patient eligibility

About

We will investigate if testosterone is preferentially given to patients at higher risk of cardiovascular events. If this is the case, then observational studies may be prone to selection bias resulting in overestimation of the cardiovascular risk associated with testosterone when compared to a healthier population not taking testosterone

Enrollment

27,778 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

All male individuals in the source population with a first testosterone use during the study period will be included as cases. The date of the GP consultation associated with the first testosterone prescription will be designated as the index day.

Exclusion criteria

Patients of less than 18 years on the index day, with less than 2-year contribution to the CPRD-HES link before the index day, or with use of testosterone before the study period will be excluded from the group of cases.